Evidence map›Paper›PMID 41933241›Full record

ArticleAnnals of surgical oncology2026

Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer: A Single-Center, Real-World Experience.

Yuntao Song, Yabing Zhang, Jiaxin Wang, Kuangyu Fei, Guohui Xu, Tianxiao Wang, Bin Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuntao SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.ORCID https://orcid.org/0000-0002-8029-7558
Yabing ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Jiaxin WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Kuangyu FeiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Guohui XuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Tianxiao WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Bin ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China. docbinzhang@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost patients with anaplastic thyroid carcinoma (ATC) present with surgically unresectable disease. The use of combined kinase inhibitors and immunotherapy in the neoadjuvant setting for ATC remains relatively unexplored.

methodsThe authors conducted a single-center, retrospective case study assessing combination neoadjuvant therapy for patients with stages IVb and IVc ATC. The primary outcomes comprised the rate of conversion to surgery, changes in tumor size and surgical morbidity parameters, as well as recurrence-free survival and overall survival.

resultsOf the 27 ATC patients treated with combination kinase inhibitors and immunotherapy, 11 (40.7%) achieved R0/R1 surgical resection. The median reduction in the largest tumor diameter was 54%. Mean surgical complexity scores decreased from baseline to surgery. According to the postoperative pathology, five patients achieved a complete response. Several major complications were observed, including one perioperative death. Neither median recurrence-free survival nor median overall survival were reached during a median follow-up period of 36 months.

conclusionsNeoadjuvant combination therapy followed by surgery enhances resectability and provides a potential curative option for patients with ATC. However, postoperative complications remain a significant concern and warrant careful attention.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNeoadjuvant TherapyProtein Kinase InhibitorsThyroid Carcinoma, AnaplasticThyroid NeoplasmsAgedAged, 80 and overCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesImmune Checkpoint InhibitorsProtein Kinase InhibitorsAnaplastic thyroid carcinomaCombination therapyImmunotherapyNeoadjuvant therapyTargeted therapy

Identifiers

PMID41933241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.